Drug intelligence / Profile preview

CHF10067

Development stage: Unknown
Lead developer: Chiesi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CHF10067 is an investigational monoclonal antibody developed by Chiesi Farmaceutici for the treatment of idiopathic pulmonary fibrosis (IPF). It is administered intravenously and has been evaluated in phase I clinical trials to assess its safety, tolerability, pharmacokinetics, and immune response in patients with IPF. The precise mechanism of action has not been disclosed publicly. As a monoclonal antibody, it is designed to recognize specific proteins on target cells and may help modulate the immune system's response in fibrotic lung disease.

Beyond the preview

Go deeper on CHF10067.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHF10067.

Explore the full profile